A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (STAR)
The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen
Sponsor: Hoffmann-La Roche
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Hoffmann-La Roche
Other Non-Squamous Non-Small Cell Lung Cancer trials with similar outcome
A observational or N/A phase clinical study on Non-Squamous Non-Small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .